Clinical Trials Logo

Filter by:
NCT ID: NCT06298630 Not yet recruiting - Thalassemia, Beta Clinical Trials

Long-term Follow-up Study of BRL-101 for TDT

Start date: December 8, 2024
Phase:
Study type: Observational

Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.

NCT ID: NCT06298318 Active, not recruiting - Hepatic Steatosis Clinical Trials

Metabolic Changes in Healthy Subjects With Acute Binge Drink

MeABD
Start date: April 27, 2024
Phase: N/A
Study type: Interventional

The goal of this double-blinded, randomized trial is to investigate the effects of acute binge drink on liver function, liver fat content and lipid metabolism in healthy young subjects. The main questions it aims to answer are: 1. if acute binge drink could alleviate liver injury and hepatic steatosis.

NCT ID: NCT06298266 Not yet recruiting - Clinical trials for Relapsed or Refractory Multiple Myeloma

To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma

Start date: March 29, 2024
Phase: Early Phase 1
Study type: Interventional

To evaluate the safety and tolerability of anti-GPRC5D-CD19 CAR-T cells infusion in subjects with relapsed and refractory multiple myeloma

NCT ID: NCT06298123 Completed - Clinical trials for Hepatocellular Carcinoma

Postoperative Adjuvant Immunotherapy for Hepatocellular Carcinoma: Risk Factor Analysis and Prognostic Modelling

Start date: February 1, 2019
Phase:
Study type: Observational

The aim of this study was to analyse the independent risk factors for hepatocellular carcinoma (HCC) patients undergoing adjuvant immunotherapy after liver resection surgery, and to develop a prognostic model based on these factors.

NCT ID: NCT06298071 Recruiting - Gout Clinical Trials

A Phase Ib Clinical Trial of Peguricase for Injection With Methotrexate in Patients With Uncontrolled Gout.

Start date: March 3, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of peguricase for injection with methotrexate in patients with gout who remain uncontrolled after standardized treatment with conventional uric acid-lowering drugs, to determine the recommended dose for phase II clinical trials, and to provide basis for formulation of administration regimen for phase II clinical trials.

NCT ID: NCT06297889 Recruiting - Player Clinical Trials

Effect of Core Strength Training on the Physical Fitness and Skills of Youth Field Hockey Players in China

Start date: February 15, 2024
Phase: N/A
Study type: Interventional

Hockey, tracing its origins back to 2000 BC, has undergone substantial evolutionary transformations throughout the centuries. Initially known by various names, the game transitioned to its modern form approximately 50 years ago, when matches were conducted on grass fields with wooden sticks. In contemporary international hockey, there has been a notable shift towards artificial grass, cultivating a dynamic and fast-paced game that places heightened demands on individual skills, tactical acumen, and physical fitness. This evolution reflects a continuous adaptation, seamlessly blending tradition with cutting-edge equipment and hybrid playing grounds. Against this backdrop, modern-day hockey programs have metamorphosed into rigorous and demanding training regimes. Athletes engaged in these programs are required not only to demonstrate outstanding physical fitness but also exhibit a high level of proficiency in the nuanced skills essential for competitive play. As hockey continues its progressive trajectory, athletes partaking in these programs must meet elevated standards, underscoring the imperative integration of both exceptional fitness levels and precise skill execution. Despite the growing emphasis on the physical and skill dimensions of hockey, a literature review uncovered a dearth of research specifically focusing on core strength training for hockey players. While core strength training has demonstrated efficacy in improving physical fitness and skill performance among athletes in other team sports, its applicability to hockey players remains underexplored. Moreover, no studies have systematically examined the impact of core strength training on the two critical variables of physical fitness and skill performance in hockey players. To address this research gap, the present study sought to investigate the effects of core strength training on the physical fitness and skill performance of youth hockey players in Gansu Province, China. By doing so, this study not only contributes valuable insights to the existing body of literature but also furnishes theoretical support for the development of hockey sport programs. The findings are anticipated to inform targeted interventions aimed at enhancing athletes' physical fitness and skill performance, ultimately fostering the progression of hockey programs within the sporting landscape of China.

NCT ID: NCT06297811 Not yet recruiting - Breast Cancer Clinical Trials

Myeloprotection With Trilaciclib in Pan-cancer Population

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The goal of this open-label randomized controlled study is to assess the myeloprotective effect of trilaciclib in pan-cancer population. The main questions it aims to answer are: - effect and safety of trilaciclib on myeloprotection in cancer patients receiving paclitaxel plus carboplatin chemotherapy - does trilaciclib 's myeloprotective efficacy in patients receiving the same chemotherapy regimen correlate with tumor type Participants will be randomized 2:1 to the treatment arm of trilaciclib in combination with a paclitaxel and carboplatin-based regimen and the control arm of a paclitaxel and carboplatin-based regimen for at least 6 cycles or until disease progression or intolerable toxicity. Patients in both groups could extend the chemotherapy cycle at the investigator 's discretion depending on the tumor type and in combination with anti-angiogenic/PD-X/anti-HER2 therapy.

NCT ID: NCT06297772 Not yet recruiting - AML, Adult Clinical Trials

Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR

Start date: June 1, 2024
Phase: Phase 3
Study type: Interventional

A multicenter, randomized, controlled clinical study comparing the efficacy and safety of allogeneic hematopoietic stem cell transplantation with decitabine-Fludarabine- busulfan (Dec-FB4) and Fludarabine-busulfan (FB4) as pretreatment regimens for the treatment of acute myeloid leukemia in adults with MR gene abnormalities

NCT ID: NCT06297655 Not yet recruiting - Hemophilia A Clinical Trials

A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A

Start date: April 2024
Phase: Phase 3
Study type: Interventional

This study is a single arm, open, multicenter clinical trial in which the previous treated severe hemophilia A patients receive recombinant human coagulation factor VIII for injection to evaluate the efficacy and safety of on-demand treatment in the event of new bleeding events. If evaluable surgical cases occur, the overall efficacy and safety of recombinant human coagulation factor VIII for injection as a replacement therapy for severe hemophilia A PTPs during the perioperative period will be evaluated.

NCT ID: NCT06297642 Recruiting - Clinical trials for Advanced Malignant Neoplasm

TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.

Start date: May 24, 2024
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and efficiency of TQB2928 injection combined with Penpulimab in the treatment of patients with advanced malignant tumors.